Abstract | BACKGROUND: METHODOLOGY/PRINCIPAL FINDINGS: CONCLUSIONS/SIGNIFICANCE: We conclude that 11β-HSD1 inhibition by CBX decreases obesity and associated co-morbidities in WNIN/Ob obese rats. Our study supports the hypothesis that inhibition of 11β-HSD1 is a key strategy to treat metabolic syndrome. Severe fat loss and glucose -intolerance by CBX treatment in lean rats suggest that chronic 11β-HSD1 inhibition may lead to insulin resistance in normal conditions.
|
Authors | Siva Sankara Vara Prasad Sakamuri, Mahesh Sukapaka, Vijay Kumar Prathipati, Harishankar Nemani, Uday Kumar Putcha, Shailaja Pothana, Swarupa Rani Koppala, Lakshmi Raj Kumar Ponday, Vani Acharya, Giridharan Nappan Veetill, Vajreswari Ayyalasomayajula |
Journal | PloS one
(PLoS One)
Vol. 7
Issue 12
Pg. e50216
( 2012)
ISSN: 1932-6203 [Electronic] United States |
PMID | 23284633
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cholesterol, HDL
- Enzyme Inhibitors
- Triglycerides
- Glycogen
- 11-beta-Hydroxysteroid Dehydrogenase Type 1
- Carbenoxolone
- Corticosterone
|
Topics |
- 11-beta-Hydroxysteroid Dehydrogenase Type 1
(antagonists & inhibitors)
- Adipocytes
(drug effects, pathology)
- Adipose Tissue
(drug effects, metabolism, pathology)
- Adrenal Glands
(drug effects, pathology)
- Animals
- Body Composition
(drug effects)
- Carbenoxolone
(adverse effects, pharmacology, therapeutic use)
- Cholesterol, HDL
(blood)
- Corticosterone
(blood)
- Eating
(drug effects)
- Enzyme Inhibitors
(adverse effects, pharmacology, therapeutic use)
- Fibrosis
(drug therapy)
- Gene Expression Regulation
(drug effects)
- Glucose Intolerance
(chemically induced, complications)
- Glycogen
(metabolism)
- Hypertrophy
(drug therapy)
- Liver
(drug effects, metabolism, pathology)
- Male
- Metabolic Syndrome
(blood, drug therapy, metabolism, pathology)
- Obesity
(complications)
- Organ Size
(drug effects)
- Rats
- Signal Transduction
(drug effects)
- Thinness
(complications)
- Triglycerides
(blood, metabolism)
|